Rebetol and Increased upper airway secretion - a phase IV clinical study of FDA data
Increased upper airway secretion is found among people who take Rebetol, especially for people who are male, 50-59 old, have been taking the drug for 1 - 6 months.
The phase IV clinical study analyzes which people take Rebetol and have Increased upper airway secretion. It is created by eHealthMe based on reports of 25,882 people who have side effects when taking Rebetol from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
25,882 people reported to have side effects when taking Rebetol.
Among them, 21 people (0.08%) have Increased upper airway secretion.
What is Rebetol?
Rebetol has active ingredients of ribavirin. eHealthMe is studying from 25,907 Rebetol users for its effectiveness, alternative drugs and more.
What is Increased upper airway secretion?
Increased upper airway secretion is found to be associated with 1,088 drugs and 611 conditions by eHealthMe.
Number of Rebetol and Increased upper airway secretion reports submitted per year:
Time on Rebetol when people have Increased upper airway secretion *:
- < 1 month: 28.57 %
- 1 - 6 months: 57.14 %
- 6 - 12 months: 0.0 %
- 1 - 2 years: 0.0 %
- 2 - 5 years: 14.29 %
- 5 - 10 years: 0.0 %
- 10+ years: 0.0 %
Gender of people who have Increased upper airway secretion when taking Rebetol *:
- female: 31.58 %
- male: 68.42 %
Age of people who have Increased upper airway secretion when taking Rebetol *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 0.0 %
- 40-49: 25.0 %
- 50-59: 41.67 %
- 60+: 33.33 %
Common drugs people take besides Rebetol *:
- Victrelis: 9 people, 42.86%
- Peg-Intron: 9 people, 42.86%
- Pegintron: 7 people, 33.33%
- Pegasys: 3 people, 14.29%
- Ambien: 2 people, 9.52%
- Prevacid: 2 people, 9.52%
- Zoloft: 1 person, 4.76%
- Elavil: 1 person, 4.76%
- Lexapro: 1 person, 4.76%
- Ibuprofen: 1 person, 4.76%
Common side effects people have besides Increased upper airway secretion *:
- Cough: 12 people, 57.14%
- Fatigue (feeling of tiredness): 11 people, 52.38%
- Weakness: 10 people, 47.62%
- Breathing Difficulty: 9 people, 42.86%
- Dizziness: 7 people, 33.33%
- Rashes (redness): 6 people, 28.57%
- Memory Loss: 6 people, 28.57%
- Influenza Like Illness: 6 people, 28.57%
- Weight Decreased: 5 people, 23.81%
- Chest Pain: 5 people, 23.81%
Common conditions people have *:
- Hepatitis C: 19 people, 90.48%
- Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 1 person, 4.76%
* Approximation only. Some reports may have incomplete information.
Do you take Rebetol and have Increased upper airway secretion?Check whether Increased upper airway secretion is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related publications that referenced our studies
- Lin SY, Lin CL, Ju SW, Wang IK, Lin CC, Lin CH, Hsu WH, Liang JA, "Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study", PloS one, 2017 Mar .
How severe was Increased upper airway secretion and when was it recovered:
Expand to all the drugs that have ingredients of ribavirin:
Alternative drugs to, pros and cons of Rebetol:
- Rebetol (25,907 reports)
Common Rebetol side effects:
- Fatigue (feeling of tiredness): 2,064 reports
- Rashes (redness): 1,812 reports
- Thrombocytopenia (decrease of platelets in blood): 1,709 reports
- Fever: 1,629 reports
- Weakness: 1,422 reports
- Depression: 1,377 reports
Browse all side effects of Rebetol:a b c d e f g h i j k l m n o p q r s t u v w x y z
Increased upper airway secretion treatments and more:
- Increased upper airway secretion (6,456 reports)
COVID vaccines that are related to Increased upper airway secretion:
- Increased upper airway secretion in Moderna COVID Vaccine
- Increased upper airway secretion in Pfizer BioNTech Covid Vaccine
- Increased upper airway secretion in Johnson and Johnson Covid Vaccine
Common drugs associated with Increased upper airway secretion:
- Humira: 550 reports
- Enbrel: 499 reports
- Spiriva: 443 reports
- Prednisone: 437 reports
- Methotrexate: 333 reports
- Aspirin: 313 reports
- Symbicort: 289 reports
- Albuterol: 286 reports
- Xolair: 239 reports
- Nexium: 238 reports
All the drugs that are associated with Increased upper airway secretion:
- Increased upper airway secretion (1,088 drugs)
Common conditions associated with Increased upper airway secretion:
- Asthma: 738 reports
- Rheumatoid arthritis: 698 reports
- Chronic obstructive pulmonary disease: 505 reports
- High blood pressure: 399 reports
- High blood cholesterol: 246 reports
- Pain: 208 reports
- Crohn's disease: 194 reports
- Multiple sclerosis: 184 reports
- Gastroesophageal reflux disease: 181 reports
- Psoriasis: 168 reports
All the conditions that are associated with Increased upper airway secretion:
- Increased upper airway secretion (611 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on ribavirin (the active ingredients of Rebetol) and Rebetol (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Tobradex and Joint Dislocation - 2 seconds ago
- Androgel and Drug Eruption - 4 seconds ago
- Nordette-28 and Fatigue - 15 seconds ago
- Methotrexate and Electrocardiogram Qt Interval Abnormal - 16 seconds ago
- Nizoral and Pustular Psoriasis - 21 seconds ago
- Urinary Tract Infection and Perirectal Abscess - 23 seconds ago
- Augmentin and Anorectal Abscess - 26 seconds ago
- High Blood Pressure and Urinary Tract Disorder - 26 seconds ago
- Hydramine and Pelvic Inflammatory Disease (Pid) - 28 seconds ago
- Lopurin and Monoclonal Immunoglobulin Present - 30 seconds ago